Employees: 487
Size Nagaileben (7447.T) is a Japan Health Care company (Medical Distributors) with a market value of $319M, the 1320th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,691 on 18 Nov 2026.
Performance Over six months the shares gained 0.3%, against -5.6% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 1.3% over the last twelve months (peer median +3.9%); the operating margin is 21.1% (peer median 1.9%).
Valuation It trades at 18.2× forward earnings against a peer median of 17.3× (5th cheapest of 9).
Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.1 points above its cost of capital (5.0% WACC).
Next results Next results expected around 17 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | ¥17.2B | ¥17.2B | ¥17.0B | ¥16.4B | ¥17.2B |
| Revenue growth | — | +1% | +3% | -4% | — |
| Gross profit | ¥6.89B | ¥6.73B | ¥6.57B | ¥6.90B | ¥7.41B |
| EBITDA | ¥3.92B | ¥3.92B | ¥3.86B | ¥4.27B | ¥4.88B |
| Net income | ¥2.65B | ¥2.65B | ¥2.57B | ¥2.82B | ¥3.23B |
| Free cash flow | n/a | ¥3.31B | ¥1.89B | ¥2.14B | ¥1.55B |
| Capital expenditure | n/a | ¥335M | ¥389M | ¥168M | ¥284M |
| Total debt | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7447.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.6% | -4.1% | 6th highest of 21 |
| 6-month return | +0.3% | -5.6% | 8th highest of 21 |
| Distance from 52-week high | -13.6% | -22.4% | 5th highest of 21 |
| Revenue growth (TTM) | +1.3% | +3.9% | 7th lowest of 21 |
| Operating margin | 21.1% | 1.9% | highest of 21 |
| Forward P/E | 18.2× | 17.3× | 5th cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | -12.7% | 4.7% | least demanding of 16 |
| Growth delivered (Del g) | -0.4% | +6.0% | 3rd lowest of 16 |
| Hurdle (Req g minus delivered) | -12.2 pp | -5.0 pp | 4th least demanding of 16 |
| ROIC minus cost of capital | +10.1 pp | -0.5 pp | highest of 21 |
| EV / EBITDA | 7.3× | 10.1× | 2nd cheapest of 4 |
| Net debt / EBITDA | -5.7× | 1.5× | least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nagaileben 7447.T | Japan | $319M | 0% | +1% | 21% | 18.2× | -12.7% | -0.4% |
| Shanghai Universal Biotech 301166.SZ | China | $337M | -15% | +15% | -4% | 25.3× | n/a | n/a |
| Rongfeng 000668.SZ | China | $297M | -32% | +61% | 14% | n/a | 9.6% | +30.0% |
| Vital KSK 3151.T | Japan | $399M | -1% | +3% | 0% | n/a | 4.7% | +2.6% |
| Excelsior Medical 4104.TW | Taiwan | $404M | +5% | +11% | 8% | n/a | -1.2% | +5.7% |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $411M | -48% | -22% | -1% | n/a | 58.3% | -7.8% |
| Gongwin Biopharm 6617.TWO | Taiwan | $412M | +87% | +12% | -530% | n/a | n/a | n/a |
| Thalys Medical Technology 603716.SS | China | $446M | -33% | -43% | -18% | n/a | n/a | n/a |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $449M | -28% | +5% | 2% | n/a | 21.1% | -18.1% |
| GKHT Medical Technology 301370.SZ | China | $525M | -24% | -11% | 1% | n/a | 13.1% | +7.5% |
| Shanghai New World 600628.SS | China | $573M | -10% | -2% | 6% | n/a | -1.6% | +1.0% |
| Arata 2733.T | Japan | $576M | -3% | +3% | 1% | 12.0× | -6.2% | +3.8% |
| Neuca NEU.WA | Poland | $795M | -9% | +8% | 2% | 15.3× | 5.3% | +8.1% |
| Shanghai Haohai Biological Technology 688366.SS | China | $878M | -24% | -9% | -2% | 16.2× | 16.9% | +13.2% |
| Entero Healthcare Solutions ENTERO.NS | India | $925M | +60% | +35% | 4% | 47.7× | 24.7% | +29.9% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 21.1× | -1.0% | +3.9% |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 9.5× | -9.7% | +6.0% |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | n/a | n/a | n/a |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | n/a | -2.7% | +17.9% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | n/a | n/a | n/a |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 18.4× | 0.0% | +6.3% |